4D Molecular Therapeutics, Inc. Common Stock (FDMT) Stock Price

FDMTStock

$15.72+117.07%52W

Market Cap$868.44M

P/E—

PEG Ratio—

Div yield—

Beta2.76

FDMT Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)56.58%

Price vs S&P 500 (4W)53.19%

VGM Score80.10

Book Value / Share (Quarterly)$8.64

P/TBV (Annual)2.28x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)200.82%

Cash Flow / Share (Quarterly)$-2.47

Price vs S&P 500 (YTD)93.24%

Net Profit Margin (TTM)-182.34%

EPS (TTM)$-2.70

10-Day Avg Trading Volume1.41M

EPS Excl Extra (TTM)$-2.70

Revenue Growth (5Y)44.32%

EPS (Annual)$-2.42

ROI (Annual)-27.71%

Net Profit Margin (5Y Avg)-87851.79%

Cash / Share (Quarterly)$7.48

Revenue Growth QoQ (YoY)21664.29%

ROA (Last FY)-24.72%

Revenue Growth TTM (YoY)383560.87%

EBITD / Share (TTM)$-2.86

ROE (5Y Avg)-32.16%

Operating Margin (TTM)-203.47%

Cash Flow / Share (Annual)$-1.90

P/B Ratio1.35x

P/B Ratio (Quarterly)1.05x

Net Income / Employee (Annual)$-714,800

EV / Revenue (TTM)6.08x

ROA (TTM)-32.55%

EPS Incl Extra (Annual)$-2.42

Current Ratio (Annual)9.39x

Quick Ratio (Quarterly)9.01x

3-Month Avg Trading Volume0.88M

52-Week Price Return117.07%

Revenue / Employee (TTM)$450,200

Tangible BV / Share (Quarterly)$7.72

P/S Ratio (Annual)7.15x

Asset Turnover (Annual)0.15x

52-Week High$16.93

Operating Margin (5Y Avg)-102464.20%

EPS Excl Extra (Annual)$-2.42

CapEx CAGR (5Y)-11.73%

26-Week Price Return67.83%

Quick Ratio (Annual)9.15x

13-Week Price Return77.10%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)9.34x

Enterprise Value$536.53M

Revenue / Share Growth (5Y)23.59%

Asset Turnover (TTM)0.18x

Book Value / Share Growth (5Y)-1.78%

Revenue / Employee (Annual)$434,700

Pretax Margin (Annual)-164.43%

Cash / Share (Annual)$6.99

3-Month Return Std Dev84.51%

Net Income / Employee (TTM)$-820,900

ROE (Last FY)-27.71%

EPS Basic Excl Extra (Annual)$-2.42

Receivables Turnover (TTM)4.92x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-2.70

Receivables Turnover (Annual)24.05x

ROI (TTM)-36.83%

P/S Ratio (TTM)6.90x

Pretax Margin (5Y Avg)-87851.79%

Revenue / Share (Annual)$1.47

Tangible BV / Share (Annual)$7.09

Price vs S&P 500 (52W)98.76%

Year-to-Date Return105.20%

5-Day Price Return4.55%

EPS Normalized (Annual)$-2.42

ROA (5Y Avg)-28.87%

Net Profit Margin (Annual)-164.43%

Month-to-Date Return51.18%

Cash Flow / Share (TTM)$-2.52

EBITD / Share (Annual)$-2.67

Operating Margin (Annual)-187.24%

ROI (5Y Avg)-32.16%

EPS Basic Excl Extra (TTM)$-2.70

P/TBV (Quarterly)1.60x

P/B Ratio (Annual)0.85x

Pretax Margin (TTM)-182.34%

Book Value / Share (Annual)$8.78

Price vs S&P 500 (13W)74.31%

Beta2.76x

P/FCF (Annual)79.40x

Revenue / Share (TTM)$1.30

ROE (TTM)-36.83%

52-Week Low$5.97

vGradeC

gGradeA

mGradeA

vgmGradeA

FDMT Earnings Surprise History

Q2 25-0.98est. -0.69

Q3 25-1.01est. -0.98

Q4 250.43est. -0.53

Q1 26-1.01est. -1.00

Q2 26-1.04est. -1.02

FDMT Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.12

4.11

Industry Peers — Biological Products(183)

Symbol	Value Score	Growth Score	Momentum Score	Price
FDMT4D Molecular Therapeutics, Inc. Common Stock	C	A	A	$15.72
AMGNAmgen Inc	C	C	B	$442.24
GILDGilead Sciences Inc	C	B	B	$148.77
MRNAModerna, Inc. Common Stock	D	C	A	$158.83
ARGXargenx SE American Depositary Shares	D	A	B	$1019.49
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$211.38
BIIBBiogen Inc. Common Stock	C	D	B	$220.77
BNTXBioNTech SE American Depositary Share	C	C	B	$114.05
NBIXNeurocrine Biosciences Inc	C	B	C	$153.37
EXELExelixis Inc	C	B	B	$56.72
HALOHalozyme Therapeutics, Inc.	C	B	A	$109.32
TECHBio-Techne Corp.	D	C	B	$72.33
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	$356.19
KYMRKymera Therapeutics, Inc. Common Stock	D	B	B	$126.64
RGENRepligen Corp	D	C	A	$181.69
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	$134.85
TWSTTwist Bioscience Corporation Common Stock	D	B	A	$151.42
PCVXVaxcyte, Inc. Common Stock	—	—	B	$61.09
QGENQIAGEN N.V.	C	C	C	$43.65
IMVTImmunovant, Inc. Common Stock	—	—	B	$43.50
IBRXImmunityBio, Inc. Common Stock	F	A	C	$8.19
SRRKScholar Rock Holding Corporation Common Stock	F	—	B	$58.25
CGONCG Oncology, Inc. Common stock	F	A	A	$78.95
CRSPCRISPR Therapeutics AG	D	B	B	$60.90
RLAYRelay Therapeutics, Inc. Common Stock	F	D	A	$20.57
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	A	$26.25
DNLIDenali Therapeutics Inc. Common Stock	F	—	B	$24.93
IOVAIovance Biotherapeutics, Inc. Common Stock	C	B	A	$8.44
BEAMBeam Therapeutics Inc. Common Stock	C	B	B	$31.03
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	$71.45
BCRXBioCryst Pharmaceuticals Inc	B	A	B	$9.83
KODKodiak Sciences Inc Common Stock	—	—	B	$39.46
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	B	$49.65
MESOMesoblast Limited American Depositary Shares	D	B	C	$17.19
VCELVericel Corporation	D	B	C	$43.22
ADMAADMA Biologics, Inc.	C	C	C	$9.72
TSHATaysha Gene Therapies, Inc. Common Stock	F	B	B	$6.20
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	$37.40
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	$3.56
VIRVir Biotechnology, Inc. Common Stock	B	B	B	$10.71
INBXInhibrx Biosciences, Inc. Common Stock	D	C	B	$122.72
ALVOAlvotech Ordinary Shares	C	D	B	$5.05
MAZEMaze Therapeutics, Inc. Common Stock	—	—	B	$30.42
NVAXNovavax Inc	B	D	C	$9.44
REPLReplimune Group, Inc.	—	—	A	$15.80
SLBTSL Science Holding Limited Ordinary Shares	—	—	F	$2.64
MGTXMeiraGTx Holdings plc Ordinary Shares	D	C	A	$14.92
VORVor Biopharma Inc. Common Stock	—	—	B	$24.01
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	A	$22.95
IMTXImmatics N.V. Ordinary Shares	C	D	C	$9.24
ODTXOdyssey Therapeutics, Inc. Common Stock	—	C	A	$26.23

About 4D Molecular Therapeutics, Inc. Common Stock

4D Molecular Therapeutics is a clinical-stage gene therapy company developing novel treatments using evolved AAV vectors across three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company's pipeline includes multiple product candidates targeting retinal diseases, heart conditions, and pulmonary disorders, leveraging its proprietary vector technology designed for targeted delivery and efficacy. With programs spanning intravitreal, intravenous, and aerosol administration routes, 4D is advancing a diversified approach to gene therapy development.